In order to remediate this issue, we propose to conjugate the iron-carrier lactoferrin (Lf), whose receptors are overexpressed on prostate cancer cell lines (Barresi & Tuccari, 1984; Tuccari & Barresi, 2011), to the surface of generation 3-diaminobutyric polypropylenimine (DAB) dendrimer carrying plasmids encoding for TNFα, TRAIL, or IL-12, and evaluate if these Lf-bearing dendriplexes could lead to an enhanced therapeutic efficacy on prostate cancer following intravenous administration. This evidence concerns the gene LTF and prostate carcinoma.